Results 1 to 10 of about 6,268 (134)

A Retrospective Observational Study on COVID-19 Patients Receiving Treatment with Nirmatrelvir/Ritonavir (PAXLOVID) [PDF]

Pulmonary Therapy
Introduction This study was undertaken in COVID-19 patients treated with and without Paxlovid™ (Paxlovid) in an outpatient setting to determine hospitalization from the community.
Mariam M. Murad, Stephen L. Atkin, Pearl W. Wasif, Alwaleed Abdulaziz Behzad, Aamal M. J. Abdulla Husain, Florence Lefebvre d’Hellencourt, Jean Joury, Mohamed Abdel Aziz, Hammam Haridy, Julia Spinardi, Lu Wang, Fiona Boland, Moe H. Kyaw, Manaf Al-Qahtani   +13 more
doaj   +2 more sources

Development and application of a UHPLC-MS/MS method for the simultaneous determination of firmonertinib and its main metabolite AST-5902 in rat plasma: a study on the in vivo drug interaction between firmonertinib and paxlovid [PDF]

Frontiers in Pharmacology
Due to the potential occurrence of drug interactions, the combined application of firmonertinib and paxlovid carries a relatively high risk. Nevertheless, as of now, there has been no comprehensive research on the interaction between firmonertinib and ...
Peng-Fei Tang, Su-Su Bao, Wei-Fei Xie, Zhong-Xiang Xiao, Xue-Meng Wu, Hong-Lei Ge   +5 more
doaj   +2 more sources

A cost-effectiveness analysis of Molnupiravir and Paxlovid for outpatient treatment of COVID-19 in three African countries [PDF]

Journal of Public Health in Africa
Background: Two COVID-19 oral antivirals (COAVs), Molnupiravir and Paxlovid, have been shown to be cost-effective in high-income countries. Aim: This study assesses the cost-effectiveness of Paxlovid and Molnupiravir, compared to usual care in three ...
Ijeoma P. Edoka, Tom Drake, Peter Baker, Raji Tajudeen, Elias Asfaw, Javier Guzman, Nicaise Ndembi, Justice Nonvignon, Jean Kaseya   +8 more
doaj   +2 more sources

Paxlovid for the treatment of severe or critical COVID-19 in children [PDF]

BMC Pediatrics
Background Paxlovid, known for its efficacy against SARS-CoV-2, is currently limited in its use for treating pediatric COVID-19, particularly in severe or critical cases.
Linjuan Xiang, Qun Wang, Yanwen Xu, Yu Tong, Yuhang Wu, Xiaoshan Zhang, Xinxin Zeng, Sheng Ye, Chenmei Zhang, Linhua Tan, Lvchang Zhu, Jing Miao, Sun Chen, Xi Zhang, Xuben Yu, Lisu Huang   +15 more
doaj   +2 more sources

Efficacy and safety of azvudine versus nirmatrelvir/ritonavir in cancer patients with COVID-19 [PDF]

Scientific Reports
Cancer significantly contributes to the unfavorable prognosis of coronavirus disease 2019 (COVID-19) patients. The efficacy and safety of azvudine and nirmatrelvir/ritonavir (Paxlovid) in cancer patients with COVID-19 remain uncertain.
Bohan Jia, Junyi Sun, Di Zhu, Ling Wang, Xiaobo Hu, Haiyu Wang, Guowu Qian, Donghua Zhang, Silin Li, Hong Luo, Shixi Zhang, Guotao Li, Guangming Li, Hongxia Liang, Zujiang Yu, Zhigang Ren   +15 more
doaj   +2 more sources

Effect of Paxlovid treatment during acute COVID-19 on Long COVID onset: An EHR-based target trial emulation from the N3C and RECOVER consortia. [PDF]

PLoS Medicine
BackgroundPreventing and treating post-acute sequelae of COVID-19 infection (PASC), commonly known as Long COVID, has become a public health priority. This study tests whether Paxlovid treatment in the acute phase of COVID-19 could help prevent the onset
Alexander Preiss, Abhishek Bhatia, Leyna V Aragon, John M Baratta, Monika Baskaran, Frank Blancero, Michael Daniel Brannock, Robert F Chew, Iván Díaz, Megan Fitzgerald, Elizabeth P Kelly, Andrea G Zhou, Thomas W Carton, Christopher G Chute, Melissa Haendel, Richard Moffitt, Emily Pfaff, N3C Consortium and the RECOVER Cohort   +17 more
doaj   +2 more sources

Paxlovid plus glucocorticoids treatment in severe Omicron infected patients with hypoxaemia: A prospective multiple-center cohort study. [PDF]

PLoS ONE
BackgroundAdministration of Paxlovid in early stage has been proved to reduce the risk of hospitalization or death by 89% in mild to moderate COVID-19 patients with high-risk. There were few evidences of Paxlovid in severe COVID-19 patients.
Yu-Ji Wang, Nan Su, Jun-Hong Jiang, Guo-Peng Xu, Ran Wang, Da-Xiong Zeng, Jiao Zhu   +6 more
doaj   +2 more sources

Real-world effectiveness and safety of oral azvudine versus Paxlovid in patients with COVID-19 and pre-existing hypertension: a multicentre, retrospective, cohort study in Henan Province, China [PDF]

BMJ Open
Objectives Azvudine and Paxlovid are the primary antiviral agents for the management of COVID-19. However, there is currently insufficient evidence regarding the effectiveness and safety of these drugs in treating COVID-19 patients with pre-existing ...
Ling Wang, Zhigang Ren, Xiaoli Jin, Hong Luo, Donghua Zhang, Ming Cheng, Fuwei Wang, Bohan Jia, Guotao Li, Mengzhao Yang, Guangming Li, Shixi Zhang, Guowu Qian, Silin Li, Hongxia Liang   +14 more
doaj   +2 more sources

Paxlovid utilization and social vulnerability: trends in Connecticut from 2022 to 2023 [PDF]

Antimicrobial Stewardship & Healthcare Epidemiology
The COVID-19 pandemic disproportionately affected vulnerable communities. Social vulnerability index (SVI) for census tracts with a Paxlovid dispensing site was higher than those without a dispensing site (0.56 vs. 0.45, P < .01).
Laura Hohenstein, Meghan Maloney, David B. Banach   +2 more
doaj   +2 more sources

A retrospective cohort study of the efficacy and safety of oral azvudine versus nirmatrelvir/ritonavir in elderly hospitalized COVID-19 patients aged over 60 years [PDF]

Acta Pharmaceutica Sinica B
Azvudine and nirmatrelvir/ritonavir (Paxlovid) are recommended for COVID-19 treatment in China, but their safety and efficacy in the elderly population are not fully known.
Bo Yu, Haiyu Wang, Guangming Li, Junyi Sun, Hong Luo, Mengzhao Yang, Yanyang Zhang, Ruihan Liu, Ming Cheng, Shixi Zhang, Guotao Li, Ling Wang, Guowu Qian, Donghua Zhang, Silin Li, Quancheng Kan, Jiandong Jiang, Zhigang Ren   +17 more
doaj   +2 more sources